Mestag Therapeutics
The company’s expertise in fibroblast biology facilitates its pipeline of first-in-class bespoke antibody programs. Mestag is accelerating the development of immunotherapies to treat the 50-70 per cent of cancer patients who fail to respond to drugs that block checkpoint protein inhibitors.
The company, led by CEO Susan Hill, is also developing immunotherapies for inflammatory disease patients to increase the rate of durable clinical remission. Mestag recently appointed a group of top cancer biology and immunology advisors to help guide its first-in-class oncology program, M300 — a tertiary lymphoid structure (TLS) induction to treat solid tumours.
In October 2024, Mestag entered into a license and collaboration agreement with MSD to identify novel targets for the development of therapies against inflammatory diseases.
